Masimo Corporation (MASI)
Here's Why Masimo (MASI) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is Why Growth Investors Should Buy Masimo (MASI) Now
Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.
Masimo (MASI) Upgraded to Strong Buy: What Does It Mean for the Stock?
Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MASI Stock Gains Following Q4 Earnings Beat, Gross Margin Contracts
Masimo's fourth-quarter 2024 results continue to benefit from the strength in its Healthcare and Non-healthcare businesses.
Masimo (MASI) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) Tops Q4 Earnings and Revenue Estimates
Masimo (MASI) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.25 per share a year ago.
Masimo Corporation (MASI) Q4 2024 Earnings Call Transcript
Masimo Corporation (NASDAQ:MASI ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Eli Kammerman - Vice President, Business Development & Investor Relations Katie Szyman - Chief Executive Officer Micah Young - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Jason Bednar - Piper Sandler Rick Wise - Stifel Michael Polark - Wolfe Research Vik Chopra - Wells Fargo Mike Matson - Needham Operator Good afternoon, ladies and gentlemen, and welcome to Masimo's Fourth Quarter and Full Year 2024 Earnings Conference Call. The company's press release is available at www.masimo.com.
Masimo Tops EPS, Revenue Expectations
Masimo (MASI -0.69%), a provider of noninvasive patient monitoring technology, released its fourth-quarter earnings for 2024, on Feb. 25, 2025. The results presented a mixed picture: strong performance was seen in its core healthcare segment, with revenue reaching $601 million, surpassing analyst expectations of $592 million.
Unlocking Q4 Potential of Masimo (MASI): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Masimo (MASI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Can Masimo (MASI) Keep the Earnings Surprise Streak Alive?
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Masimo (MASI) is a Great Momentum Stock to Buy
Does Masimo (MASI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Masimo Taps Katie Szyman as Permanent CEO
Szyman currently serves as the worldwide president of Advanced Patient Monitoring at Becton Dickinson and Co.
